Survodutide is an investigational once-weekly GLP-1/glucagon dual receptor agonist being developed by Boehringer Ingelheim and Zealand Pharma for obesity and metabolic dysfunction-associated steatohepatitis (MASH). It is not approved by any regulator as of 2026; it is being evaluated in Phase 3 trials.

Is Survodutide approved for medical use?

Survodutide is investigational: it is being studied in clinical research and is not an approved medicine. United States (FDA): Investigational; not approved. Being evaluated in a Phase 3 program (SYNCHRONIZE) for obesity, with additional trials in MASH. European Union (EMA): Not authorized; investigational, no marketing authorization. Australia (TGA): Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.

Is Survodutide legal in Australia?

Survodutide in Australia (TGA): Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.

Is Survodutide banned in sport?

Survodutide under the World Anti-Doping Agency (WADA) code: Not listed on the WADA Prohibited List. As an investigational incretin-class agent (a GLP-1/glucagon dual agonist) it is not a banned substance.

Dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors (investigational metabolic peptide)

Survodutide

Investigationalaka BI 456906

Survodutide is an experimental single-molecule dual agonist of the GLP-1 and glucagon receptors studied for chronic weight management and for MASH (formerly NASH). A published Phase 2 trial in MASH reported improvements in liver histology, and Phase 2 obesity data showed substantial weight reductions; a Phase 3 program (SYNCHRONIZE) is ongoing. It remains investigational and is not authorized for clinical use.

Compare

Retatrutide vs Survodutide

Mechanism

In plain terms, survodutide mimics two hormones at once to reduce appetite and influence how the liver and body handle fat and sugar. Technically, it is a synthetic peptide that simultaneously agonizes the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. GLP-1 activity promotes satiety and glucose-dependent insulin secretion, while glucagon-receptor agonism is thought to increase energy expenditure and hepatic lipid metabolism, a combination proposed to drive weight loss and reduce liver fat.

Regulatory Status by Region

United States (FDA)Investigational; not approved. Being evaluated in a Phase 3 program (SYNCHRONIZE) for obesity, with additional trials in MASH.
Australia (TGA)Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.
European Union (EMA)Not authorized; investigational, no marketing authorization.
WADANot listed on the WADA Prohibited List. As an investigational incretin-class agent (a GLP-1/glucagon dual agonist) it is not a banned substance.

See the full regulatory status matrix

Key Studies

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (Sanyal et al.) (opens in a new tab) (N Engl J Med 2024)

Related Clinical Trials

Latest research

Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. (opens in a new tab)
Nature medicine · Aug 25, 2026
Survodutide Once Weekly for the Treatment of Adults with Obesity. (opens in a new tab)
The New England journal of medicine · Aug 20, 2026
Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN). (opens in a new tab)
Diabetes therapy : research, treatment and education of diabetes and related disorders · Aug 14, 2026

See all recent Survodutide research

Common Questions

What is Survodutide?: Survodutide is an investigational once-weekly GLP-1/glucagon dual receptor agonist being developed by Boehringer Ingelheim and Zealand Pharma for obesity and metabolic dysfunction-associated steatohepatitis (MASH). It is not approved by any regulator as of 2026; it is being evaluated in Phase 3 trials.
Is Survodutide approved for medical use?: Survodutide is investigational: it is being studied in clinical research and is not an approved medicine. United States (FDA): Investigational; not approved. Being evaluated in a Phase 3 program (SYNCHRONIZE) for obesity, with additional trials in MASH. European Union (EMA): Not authorized; investigational, no marketing authorization. Australia (TGA): Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.
How does Survodutide work?: In plain terms, survodutide mimics two hormones at once to reduce appetite and influence how the liver and body handle fat and sugar. Technically, it is a synthetic peptide that simultaneously agonizes the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor.
Is Survodutide legal in Australia?: Survodutide in Australia (TGA): Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.
Is Survodutide banned in sport?: Survodutide under the World Anti-Doping Agency (WADA) code: Not listed on the WADA Prohibited List. As an investigational incretin-class agent (a GLP-1/glucagon dual agonist) it is not a banned substance.